| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T344 |
0-137 |
Sentence |
denotes |
Finally, soluble and catalytically inactive forms of ACE2 have been shown to be potent inhibitors of SARS-CoV infection products [19,21]. |
| T345 |
138-238 |
Sentence |
denotes |
An approach that could be pursued (in combination with other therapies) to inhibit SARS-CoV-2 entry. |
| T346 |
239-455 |
Sentence |
denotes |
Indeed, soluble forms of ACE2 are expected to protect from viral infection and a similar strategy using a recombinant form of human ACE2 has been proposed not only in COVID-19, but also in ARDS and PAH [108,133,134]. |
| T347 |
456-586 |
Sentence |
denotes |
However, it is possible that catalytic active form of ACE2 might favour adverse effects in these specific pathological conditions. |
| T348 |
587-897 |
Sentence |
denotes |
To this regard, a clinical trial using recombinant hACE2 protein has been recently started (ClinicalTrials.gov number, NCT04287686) in COVID-19 patients and pilot clinical trials of rhACE2 in ARDS and PAH started in 2017 and 2018, respectively [108,134]; unfortunately, no conclusive results are available yet. |
